Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.
Hartung HP, Kappos L, Goodin DS, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, White R, Bogumil T, Beckmann K, Stemper B, Suarez G, Sandbrink R, Pohl C. Hartung HP, et al. Among authors: goodin ds. J Neurol. 2015 Nov;262(11):2466-71. doi: 10.1007/s00415-015-7862-9. Epub 2015 Aug 5. J Neurol. 2015. PMID: 26239222 Free PMC article.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B; EVIDENCE Study Group. EVidence of Interferon Dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Panitch H, et al. Among authors: goodin ds. Neurology. 2002 Nov 26;59(10):1496-506. doi: 10.1212/01.wnl.0000034080.43681.da. Neurology. 2002. PMID: 12451188 Clinical Trial.
Neuromyelitis optica.
Cree BA, Goodin DS, Hauser SL. Cree BA, et al. Among authors: goodin ds. Semin Neurol. 2002 Jun;22(2):105-22. doi: 10.1055/s-2002-36534. Semin Neurol. 2002. PMID: 12524556 Review.
The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Frohman EM, et al. Among authors: goodin ds. Neurology. 2003 Sep 9;61(5):602-11. doi: 10.1212/01.wnl.0000082654.99838.ef. Neurology. 2003. PMID: 12963748
The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Goodin DS, et al. Neurology. 2003 Nov 25;61(10):1332-8. doi: 10.1212/01.wnl.0000095425.84407.39. Neurology. 2003. PMID: 14638950 Review.
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G; EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study Group; University of British Columbia MS/MRI Research Group. Schwid SR, et al. Arch Neurol. 2005 May;62(5):785-92. doi: 10.1001/archneur.62.5.785. Arch Neurol. 2005. PMID: 15883267 Clinical Trial.
194 results